Cyclin-dependent kinase inhibitors (CDKN) may be causally related to atherosclerosis [3], [59], although the exact role of CDNK1A (adjacent to MAP3K6 and SLC10A6 in Figure 2) remains unclear. The gene discussed is MAP3K6; the disease is atherosclerosis.